Bicara Therapeutics (BCAX) director receives 19,475 stock options at $20.56 strike

Rhea-AI Filing Summary

Bicara Therapeutics Inc. director Kiran Mazumdar-Shaw received a stock option grant covering 19,475 shares of common stock. The option has an exercise price of $20.56 per share and expires on June 9, 2036.

The shares underlying this option vest on the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to her continued service on that vesting date. Following this grant, she holds 19,475 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mazumdar-Shaw Kiran

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,475	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,475 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 19,475 options Exercise price: $20.56 per share Expiration date: June 9, 2036 +2 more

5 metrics

Stock options granted 19,475 options Stock Option (Right to Buy) grant to director

Exercise price $20.56 per share Exercise price of stock option grant

Expiration date June 9, 2036 Option expiration for granted stock options

Vesting date trigger June 9, 2027 Latest vesting date or earlier next annual meeting

Derivative holdings after grant 19,475 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "20.5600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc."

vesting financial

"shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount": 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar-Shaw Kiran

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20.56	06/09/2026		A		19,475		(1)	06/09/2036	Common Stock	19,475	$0	19,475	D

Explanation of Responses:

1. 1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Remarks:

	/s/ Ryan Cohlhepp, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bicara Therapeutics (BCAX) disclose about Kiran Mazumdar-Shaw in this Form 4?

Bicara Therapeutics reported that director Kiran Mazumdar-Shaw received a stock option grant for 19,475 shares at a $20.56 exercise price. The options are compensation-related and increase her derivative holdings to 19,475 options directly.

How many Bicara Therapeutics (BCAX) options were granted to Kiran Mazumdar-Shaw?

She was granted stock options covering 19,475 shares of Bicara Therapeutics common stock. These options give her the right to buy those shares at a fixed exercise price of $20.56 per share before the stated expiration date.

What is the exercise price and expiration date of the BCAX options granted?

The stock options have an exercise price of $20.56 per share and expire on June 9, 2036. This means she can choose to buy shares at $20.56 any time before that expiration, once the options have vested.

When do Kiran Mazumdar-Shaw’s Bicara Therapeutics (BCAX) options vest?

The options vest on the earlier of June 9, 2027 or the date of Bicara’s next Annual Meeting of Stockholders. Vesting is also conditioned on her continued service with the company through the applicable vesting date.

Is Kiran Mazumdar-Shaw’s BCAX Form 4 transaction a purchase or a grant?

The Form 4 reports a grant or award acquisition, not an open-market purchase. She received 19,475 stock options as compensation, coded as an “A” transaction, with no cash paid and a $20.56 exercise price for future share purchases.

How many Bicara Therapeutics (BCAX) derivative securities does Kiran Mazumdar-Shaw hold after this grant?

After the reported transaction, she holds 19,475 derivative securities directly. These represent stock options giving her the right to acquire an equal number of Bicara Therapeutics common shares at the fixed $20.56 exercise price.